New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm

JCI Insight. 2020 Jul 23;5(14):e140971. doi: 10.1172/jci.insight.140971.

Abstract

Purinergic signaling is discussed as a potential therapeutic target to reduced COVID-19 severity.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenosine Diphosphate / immunology
  • Adenosine Triphosphate / immunology
  • Betacoronavirus
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / immunology*
  • Cytokine Release Syndrome / drug therapy
  • Cytokine Release Syndrome / immunology*
  • Dipyridamole / therapeutic use*
  • Drug Repositioning
  • Extracellular Traps / immunology
  • Humans
  • Pandemics
  • Phosphodiesterase Inhibitors / therapeutic use
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / immunology*
  • Purinergic Agents / therapeutic use*
  • Thrombosis / drug therapy
  • Thrombosis / immunology*

Substances

  • Phosphodiesterase Inhibitors
  • Purinergic Agents
  • Adenosine Diphosphate
  • Dipyridamole
  • Adenosine Triphosphate

Supplementary concepts

  • COVID-19
  • COVID-19 drug treatment
  • severe acute respiratory syndrome coronavirus 2